These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31583437)

  • 1. Enhanced Production of Shigella flexneri Polysaccharide from a Newly Devised Silicate Method as a Potential Vaccine Conjugate.
    Narayana PVSLSS; Ray Dutta J
    Curr Microbiol; 2019 Dec; 76(12):1398-1406. PubMed ID: 31583437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel method for purification of Vi capsular polysaccharide produced by Salmonella enterica subspecies enterica serovar Typhi.
    Kothari S; Kothari N; Kim JA; Lee E; Yoon YK; An SJ; Jones C; Choe WS; Carbis R
    Vaccine; 2013 Oct; 31(42):4714-9. PubMed ID: 23994374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoconjugation of Shigella flexneri type 2a O-polysaccharide with CRM
    Narayana PVSLSS; Dutta JR
    Biologicals; 2021 Jul; 72():1-9. PubMed ID: 34247915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The optimization of the technology for culturing vaccinal strains of Shigella flexneri].
    Basnak'ian IA; Miriasova LV; Sokolova TV; Ian'kova MM; Kalina NG; Elkina SI; Sergeev VV
    Zh Mikrobiol Epidemiol Immunobiol; 1993; (5):6-10. PubMed ID: 8067146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of Toll-like receptor-2-activating bacterial lipoproteins in Shigella flexneri culture supernatants.
    Aliprantis AO; Weiss DS; Radolf JD; Zychlinsky A
    Infect Immun; 2001 Oct; 69(10):6248-55. PubMed ID: 11553567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Shigella dysenteriae serotype 1 O-antigenic polysaccharide by Shigella flexneri aroD vaccine candidates and different S. flexneri serotypes.
    Fält IC; Schweda EK; Klee S; Singh M; Floderus E; Timmis KN; Lindberg AA
    J Bacteriol; 1995 Sep; 177(18):5310-5. PubMed ID: 7545156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.
    Dharmasena MN; Osorio M; Takeda K; Stibitz S; Kopecko DJ
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29046309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of culture media for enrichment and isolation of Shigella sonnei and S. flexneri.
    Uyttendaele M; Bagamboula CF; De Smet E; Van Wilder S; Debevere J
    Int J Food Microbiol; 2001 Nov; 70(3):255-65. PubMed ID: 11764191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation.
    Kämpf MM; Braun M; Sirena D; Ihssen J; Thöny-Meyer L; Ren Q
    Microb Cell Fact; 2015 Jan; 14():12. PubMed ID: 25612741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biofilm model experiments in vitro with Escherichia coli and Shigella strains.
    Kétyi I
    Acta Microbiol Hung; 1989; 36(1):41-50. PubMed ID: 2690554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of production and control methods of live dysentery vaccine Vadizen (Shigella flexneri 2a T32-Istrati).
    Meitert T; Ciudin L; Pencu E; Tonciu M; Gheorghe G
    Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):357-67. PubMed ID: 6400311
    [No Abstract]   [Full Text] [Related]  

  • 14. HPAEC-PAD quantification of Haemophilus influenzae type b polysaccharide in upstream and downstream samples.
    van der Put RM; de Haan A; van den IJssel JG; Hamidi A; Beurret M
    Vaccine; 2015 Nov; 33(48):6908-13. PubMed ID: 25045809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV; Turbyfill KR
    Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of transcriptional regulatory elements of glutamate-dependent acid-resistance systems of Shigella flexneri and Escherichia coli O157:H7.
    Bhagwat AA; Bhagwat M
    FEMS Microbiol Lett; 2004 May; 234(1):139-47. PubMed ID: 15109732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunochemical characteristics of Shigella sonnei and serotype 6 Shigella flexneri lipopolysaccharides and enterobacterial common antigen.
    Romanowska E; Katzenellenbogen E; Lugowski C; Gamian A; Bogulska M
    Arch Immunol Ther Exp (Warsz); 1978; 26(1-6):249-54. PubMed ID: 86336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R
    J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
    Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA
    J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine.
    Phalipon A; Costachel C; Grandjean C; Thuizat A; Guerreiro C; Tanguy M; Nato F; Vulliez-Le Normand B; Bélot F; Wright K; Marcel-Peyre V; Sansonetti PJ; Mulard LA
    J Immunol; 2006 Feb; 176(3):1686-94. PubMed ID: 16424198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.